Pamgene Bv

Erasmus University Medical Center Rotterdam

Universiteit Utrecht Holding B.v.

Stichting Het Nederlands Kanker Instituut

Oslo University Hospital

Leiden University Medical Center

Robby Ruijtenbeek

Richard De Wijn

Maria Helena Hilhorst

Pieter Jacob Boender

Robertus Matthias Joseph Liskamp

Marinus Gerardus Johannes Van Beuningen

Jeroen Van Ameijde

Adrianus Henricus Josephus Mathijssen

Joan Gertrudis Jacobus Victor Aerts

Dirgje Maria Adriana Van Den Heuvel

Sigurd Folkvord

Anne Hansen Ree

Houke Marian Klomp

Michael Maria Van Den Heuvel

Johannes Wilhelmus Maria Martens

Johannes Albert Foekens

Arzu Umar

René Houtman

Liesbeth Coosje Hovestad-Bijl

Elizabeth M E Verdegaal

Sjoerd H Van Der Burg

The present invention relates to a method for determining or predicting the response of a patient diagnosed with non-small-cell lung carcinoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non-small-cell lung carcinoma to specific medicaments. More specifically, the present invention provides methods which measure kinase-activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in blood samples of said patients.

Method for predicting the response of non-small-cell lung carcinoma patients to a medicament

The present invention relates to a method for determining or predicting the response of a patient diagnosed with melanoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with melanoma to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.

Method for predicting the response of melanoma patients to targeted pharmacotherapy

The present invention relates to a method and tools which allow the kinetic monitoring of hydrolase enzyme activity. The present invention also aims to provide synthetic peptides and peptide residues modified such that they can be used in assays for monitoring hydrolase enzyme activity, and preferably phosphatase activity. Also claimed are modified tyrosine amino acid derivatives of formula (IV), wherein Y is chosen from &#x2014;POwith y equal to 2 or 3 and esters thereof, &#x2014;SOwith z equal to 2 or 3 and esters thereof, a carbohydrate or carbohydrate derivatives; and; wherein Xand/or Xis selected from &#x2014;N, &#x2014;NO, &#x2014;CI, or &#x2014;CN, &#x2014;SCN, a Cto Calkyl, or H, wherein either Xor Xis not H. 

Modified tyrosine amino acids, peptides containing them, and their use for detecting hydrolase enzyme activity

The present invention relates to methods for measuring compound efficacy and potency on nuclear receptor-co-regulator interaction, comprising the steps of (a) co-incubating at least one nuclear receptor and at least one compound under conditions that allow interaction; (b) co-incubating the nuclear receptor-compound mixture of step (a) with an array of co-regulators, under conditions that allow compound modulated receptor-co-regulator interaction; (c) determination of compound-modulated receptor-co-regulator interaction in function B of co-regulator concentration, and (d) determination of compound-modulated receptor-co-regulator interaction in function of compound concentration; wherein steps (c) and (d) are performed in a single assay.

Nuclear receptor assay

The present invention relates to a method for determining the estrogen receptor status of patients suffering from breast cancer. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with breast cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples obtained from patients diagnosed with breast cancer.

Method for determining the estrogen receptor status of breast cancer

The present invention relates to a method for determining the survival prognosis of patients suffering from non-small cell lung cancer. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels in response to a kinase inhibitor and profiles in samples obtained from patients diagnosed with non-small cell lung cancer. The present invention also provides methods for predicting the response of a patient diagnosed with non-small cell lung cancer to a medicament.

Method for determining survival prognosis of patients suffering from non-small cell lung cancer (NSCLC)

The present invention relates to a method for determining or predicting the response of a patient diagnosed with non small cell lung cancer to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non small cell lung cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.

Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy

The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.

Method for predicting the response of locally advanced rectal cancer to chemoradiotherapy

Growing community of inventors

Utrecht, Netherlands

Robby Ruijtenbeek